Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.
CELZ · Creative Medical Technology Holdings, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Creative Medical Technology Holdings, Inc. stockholders will vote on December 28, 2026 to elect five directors and approve an evergreen provision adding up to 5% of outstanding common shares annually from January 1, 2027 through January 1, 2031.
Creative Medical Technology Holdings reported no revenue and a $2,663,478 net loss for the three months ended September 30, 2026, versus $1,235,934 a year earlier. Available cash and US Treasuries totaled $6,845,741.
On September 24, 2026, Creative Medical Technology Holdings, Inc. purchased 4,000,000 BioDefense, Inc. shares for $200,000 and 1,000,000 company shares, increasing its ownership to 16,000,000 shares, or 80%.